SPI Infoamtion

Table of Contents

1. Executive Summary
1.1 Stem Cells Market Review
1.2 Crucial Aspects of the Stem Cells Market
1.3 Aims, Scope and Format of this Report
1.3.1 Speculative Aspects of Assessing the Stem Cell Field
1.3.2 Chapter Outline
1.4 Research and Analysis Methods

2. Stem Cells: An Introduction
2.1 Stem Cells in 2010: Overview of the Sector
2.2 The Basics: What Are Stem Cells?
2.3 Stem Cell Potency
2.3.1 Totipotency
2.3.2 Pluripotency
2.3.3 Multipotency
2.3.4 Oligopotency
2.3.5 Unipotency
2.3.6 Stem Cells and Progenitor Cells
2.4 Embryonic Stem Cells
2.4.1 Abortion Debates, IVF, and Embryonic Stem Cells
2.4.2 Harvesting Human Eggs
2.5 Adult Stem Cells
2.5.1 Sources of Adult Stem Cells

3. Issues Affecting the Stem Cells Market, 2010
3.1 Strengths
3.1.1 Stem Cells Have Great Therapeutic Potential
3.1.2 Stem Cells Could Revolutionise Our Understanding of Disease
3.1.3 Animal Models Yield Impressive Results
3.1.4 Stem Cells Already Have Some Therapeutic Applications
3.1.5 The Stem Cells Field Has Strength in Numbers
3.1.6 Discoveries Are Being Made at a Rapid Rate
3.1.7 Adult Stem Cells: Fewer Ethical Controversies
3.1.8 Many Governments Support Adult Stem Cell Research
3.1.9 Stem Cells Have Proven Uses and Marketability Beyond Their Directly Therapeutic Applications
3.1.10 The Market Offers Multiple Business Models
3.2 Weaknesses
3.2.1 Therapies Take Time
3.2.2 Stem Cells and Cancer
3.2.3 The Safety-First Approach
3.2.4 Embryonic Stem Cell Supply Problems
3.2.5 Business Model Problems with Autologous Therapies
3.2.6 Donor Rejection Risk with Allogeneic Therapies
3.2.7 The Research Field is Fragmented
3.2.8 The IP Minefield
3.2.9 Government Money is Required: Little Venture Capital - Yet
3.2.10 Problems Adapting Pharmaceutical Business Model to Stem Cells
3.3 Opportunities
3.3.1 Therapies: Almost Anything Could Happen
3.3.2 The Attractions of the Stem Cells Market
3.3.3 Asia Harnesses Stem Cells Opportunities
3.3.3.1 China: Favourable Regulations
3.3.3.2 Japan: Liberal hESC Policy
3.3.3.3 Singapore: Advanced and Prominent
3.3.3.4 South Korea: Stem Cells a National Priority
3.3.3.5 India: First Official Research Hub Opened in 2009
3.3.3.6 Israel: at The Forefront
3.3.3.7 Gulf Countries: Funding Stem Cell Research
3.3.4 Adipose Tissue Opportunities for IPSCs
3.3.5 Beyond Pluripotency
3.3.6 Pharmaceutical Laws Do Not Apply to Stem Cell Therapies
3.3.7 Unique Disease Modelling Possibilities With IPS Cells
3.3.8 High Net-Worth Individuals: A Possible Source of Stem Cell Capital
3.3.9 The Opportunity to Get There First
3.3.10 Public Perception of Stem Cells Represents an Opportunity
3.4 Threats
3.4.1 The Risks of the Regulatory Environment
3.4.1.1 North America
3.4.1.2 Europe
3.4.2 Lack of Embryonic Stem Cell Diversity in US Research
3.4.3 Not Everyone Can Succeed in The Stem Cells Market
3.4.4 The Risk of Public Disenchantment
3.4.5 High-Profile Failures in Stem Cell Supply
3.4.6 High-Profile Failures in Stem Cell Therapies
3.4.7 Scare Stories and Perception Problems
3.4.8 Economic Instability
3.4.9 Market Fluidity is a Threat
3.4.10 Are Stem Cells Too Revolutionary for the Existing Pharmaceuticals Model?

4. The Stem Cell Market in 2010
4.1 The Stem Cell Market Was Worth Around $2.8bn in 2009
4.1.1 Where The Money is: Divisions of the Stem Cells Market in 2010
4.2 Stem Cell Therapies
4.2.1 Existing Stem Cell Therapies Market
4.2.2 Diseases Treated With Adult Stem Cells In 2010
4.2.3 Bone Marrow Transplants
4.2.3.1 The Transplant Process
4.2.3.2 The Results
4.2.4. Peripheral Blood Stem Cell Transplants
4.2.5 Cord Blood Stem Cell Transplants
4.2.6 Allogeneic Transplants vs. Autologous Transplants
4.2.6.1 Allogeneic Transplants are Better for Killing Cancer
4.2.6.2 The Problem with Allogenic Transplants: Graft-versus-Host Disease and Host-versus-Graft Disease
4.2.6.3 Saviour-Siblings: Stem Cells from a Sibling, Created or Chosen to be a Saviour
4.2.6.4 UK Cases and Rules on Saviour Siblings
4.2.7 Other Surgery Involving Stem Cells
4.2.8 Osteocel and other Bone Regeneration Products
4.2.9 Stem Cells and Regenerative Medicine
4.2.9.1 Organogenesis
4.2.9.2 Stem Cell Therapeutics
4.2.9.3 CEL-SCI Corporation
4.2.9.4 Osteotech
4.2.9.5 RegeneRx
4.2.9.6 RTI Biologics
4.2.9.7 Biomimetic Therapeutics
4.2.9.8 Fibrocell
4.2.10 Stem Cell Cosmetics
4.2.10.1 Breast Enhancement
4.2.10.2 Topical "Stem Cell" Preparations
4.2.11 Unregulated Stem Cells Therapies
4.3 Stem Cell Services
4.3.1 The Market for Stem Cell Services
4.3.2 Some of the Companies in the Stem Cell Services Market
4.3.2.1 Cellular Dynamics International: Cardiomyocyte Technology
4.3.2.2 Fate Therapeutics: Stem Cells for Drug Discovery
4.3.2.3 International Stem Cell Corporation: Parthenogenetic Cell Line Bank
4.3.2.4 Axiogenesis: Research Tools
4.3.2.5 Vitro Biopharma: Longer-Lasting Cell Line Expansion Periods
4.3.2.6 CellCyte Genetics: Expansion Bioreactor
4.3.2.7 MultiCell Technologies: Liver Stem Cell Lines
4.3.2.8 Stemgent: Stem Cell Scientists
4.3.2.9 Regenetech: Stem Cell Expansion Leaders
4.3.2.10 Pfizer/Novocell: Pancreatic Cell Lines
4.3.2.11 Biotime: 200+ Patent Portfolio
4.3.2.12 StemLifeLine: Embryonic Stem Cells Without Embryo Destruction?
4.3.2.13 Stem Cell Innovations (SCI): PluriCells Platform
4.3.2.14 HyClone/Thermo Fisher Scientific: 40 Years of Cell Culture Products
4.3.2.15 Merck/Calibochem/Stem Cell Sciences: Drug Screening Assays
4.3.2.16 Stemride International Limited (SIL) and Reproductive Genetics Institute, Chicago: Normal and Abnormal Cell Lines
4.3.2.17 ES Cell International, Singapore: Hoping for the First Marketed Product Including Embryonic Stem Cells
4.3.2.18 StemCell Technologies: ES Cells and Cell Culture Supplies
4.3.2.19 Bio-Matrix Scientific Group: Cryopreservation
4.4 Blood Banking
4.4.1 Biological Insurance: Private Blood Banking
4.4.2 Umbilical Cord Banking: The Controversies
4.4.2.1 US Oversight of Cord Blood Stem Cells
4.4.3 The Market for Blood Banking
4.4.4 Companies in the Field
4.4.4.1 Cord Blood America: Looking Towards the Chinese Market
4.4.4.2 ViaCord: 145,000 Blood Units in Storage
4.4.4.3 Cryo-Cell International: The First Cord Blood Bank
4.4.4.4 Stem Cell Authority: Exclusive Stem Cells
4.4.4.5 LifebankUSA: Placenta-Cord Banking

5. The New Stem Cell Therapies I: Companies and Business Models
5.1 In Search of a Stem Cells Business Model
5.1.1 Embryonic or Adult?
5.2 Stem Cell Companies in the Media Spotlight
5.2.1 Towards the First Human Trials of Embryonic Stem Cells
5.2.2 Adult Stem Cells: Collaborations with Pharmaceutical Giants
5.3 Embryonic Stem Cells
5.3.1 Geron: First Embryonic Stem Cell Trial
5.3.1.1 Geron and GE Healthcare
5.3.2 Advanced Cell Technology (ACT)
5.3.2.1 Competition for ACT in Macular Degeneration Treatment
5.3.2.2 ACT Deals with Other Companies
5.3.3 Novocell: Looking to Follow Geron and ACT in Embryonic Stem Cells Trials
5.3.3.1 Novocell's Collaborations with Pharmaceutical Leaders
5.3.4 CellCure Neurosciences
5.3.5 Royan Institute (Tehran)
5.3.6 Reliance Life Sciences, India
5.4 Adult Stem Cell Therapies: Allogeneic
5.4.1 Osiris: First to Market with Stem Cells
5.4.1.1 Osiris and NuVasive
5.4.1.2 Osiris and Genzyme
5.4.1.3 Prochymal: Great Promise but How is Work Shaping Up?
5.4.1.4 What Next for Prochymal?
5.4.2 Athersys
5.4.2.1 Multistem: an Off-The-Shelf Allogeneic Stem Cell Therapy
5.4.3 StemCells
5.4.4 MediStem (MediStem Laboratories, Inc.)
5.4.5 ReNeuron
5.4.6 Pluristem Therapeutics
5.4.7 Amstem International (Stem Cell Therapy International/Histostem)
5.4.8 Neuralstem
5.4.9 Garnet BioTherapeutics/Neuronyx
5.4.10 HepaLife Technologies
5.5 Adult Stem Cells: Autologous Therapies
5.5.1 Opexa Therapeutics
5.5.1.1 Tovaxin
5.5.2 Cellerix: Ontaril has EMEA Orphan Drug Status
5.5.3 Aastrom Biosciences
5.5.4 Bioheart
5.5.5 Cardiogenesis: Autologous Medical Devices
5.5.6 BrainStorm Cell Therapeutics
5.5.7 Cytori Therapeutics
5.5.8 TCA Cellular Therapy
5.5.9 Autologous Cell Storage
5.5.9.1 LifeStem: Two Sources of Stem Cells Preserved
5.5.9.2 Neostem: Success with Bone Marrow Stem Cell Storage
5.5.9.3 Thermogenesis: Autologous Cryopreservation
5.5.9.4 Biogenea-CellGenea: Leading Stem Cell Research Facility in the EU

6. The New Stem Cell Therapies II: Indications
6.1 The Growth of the Stem Cells Market to 2025
6.2 Near-Term Indications
6.2.1 Cancer
6.2.1.1 Cancer Stem Cells
6.2.2 Immune Disorders
6.2.3 Eye Diseases
6.2.4 Orthopaedics
6.2.5 Diabetes
6.2.6 Other Likely Near-Term Indications
6.2.6.1 Acute Radiation Syndrome
6.3 Cardiovascular Diseases
6.4 Brain and Central Nervous System Diseases
6.4.1 Amyotrophic Lateral Sclerosis (ALS, Lou Gherig's Disease)
6.4.2 Multiple Sclerosis
6.4.3 Alzheimer's Disease
6.4.4 Cerebral Palsy
6.4.5 Pelizaeus-Merzbacher Disease (PMD)
6.4.6 Parkinson's Disease
6.4.7 Spinal Cord Injury
6.5 Growing Organs
6.6 Other Possible Indications for Stem Cells
6.6.1 Autism
6.6.2 HIV and Other Viral Diseases
6.6.3 Fertility Treatment

7. Interviews with Experts
7.1 Dr Johan Luthman, Merck Serono
7.1.1 Difficulties of Translational Medicine
7.1.2 Differences Between Technology and Media Perceptions
7.1.3 Confusion in the Media
7.1.4 Stem Cells and Neurologic Disorders
7.1.4.1 Which Neurological Disorders will be Treated First?
7.1.4.2 Multiple Sclerosis
7.1.5 Why Stem Cell Results Take a Long Time
7.1.6 When Stem Cell Therapies Will Reach the Market
7.1.7 The Distinction between Regenerative Medicine and Stem Cell Therapies
7.2 Dr Stephen Minger, Wolfson Centre for Age-Related Diseases, King's College London
7.2.1 On Whether Adult or Embryonic Stem Cells Should Receive More Funding/Support
7.2.2 Cord Blood and Embryonic Stem Cells
7.2.3 The Need for More Immunological Assays
7.2.4 How Long Until there are Human Stem Cell Therapies?
7.2.5 Cord Blood as a Source of Stem Cells
7.2.6 Private Cord Blood Banking
7.2.7 Therapeutic Cloning
7.2.7.1 Therapeutic Cloning and Tissue Type Cell Lines
7.2.8 Promising and Unusual Immunological Properties of Embryonic Stem Cells
7.2.9 Mesenchymal Stem Cells and Inflammation
7.2.10 On the Use of Foreskin Fibroblasts
7.3 Gregory Bonfiglio, Proteus Venture Partners
7.3.1 On the Terms "Stem Cell Therapy" and "Regenerative Medicine"
7.3.2 On "Near Term" Applications
7.3.3 Value-Creation Curve for Venture Capital in Stem Cells
7.3.4 On There Being No Known Limits on Stem Cell Possibilities
7.3.5 On Stem Cells in 25 Years
7.3.6 Funding as a Primary Limitation?
7.3.7 Stem Cells in Multiple Sclerosis and Diabetes Type 1
7.3.8 Cord Blood
7.3.9 Extracellular Matrixes
7.3.10 Disease-Specific Cell Lines
7.3.11 Adult vs. Embryonic Stem Cells
7.3.12 Capital for Stem Cell and Regenerative Medicine Research
7.4 Josephine Quintavalle, Founder of Comment on Reproductive Ethics (CORE)
7.4.1 Embryonic Stem Cells and Dehumanisation
7.4.2 HFEA Regulation on Embryo Destruction
7.4.3 Economics and Scientific Effectiveness
7.4.4 Cord Blood
7.4.5 Adult Stem Cell Therapies and the Economics of Therapy
7.4.6 Public, Private and Private/Public Cord Blood Banks
7.4.7 International Studies and International Communication

8. Conclusions
8.1 The Stem Cell Market in 2010 is Small, But Will Grow Rapidly
8.2 The Stem Cell Therapies Market is on The Brink of Significant Growth
8.3 Induced Pluripotent Adult Stem Cells May Revolutionise the Market
8.4 The Sector Has Marked Uncertainties, But Many Opportunities

List of Tables
Table 2.1 Potency and Source of Stem Cells
Table 2.2 Germ Layers and Their Associated Types of Cells and Organs
Table 3.1 SWOT Analysis of the Stem Cells Sector, 2010
Table 4.1 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025
Table 4.2 Some Diseases That Have Been Treated With Adult Stem Cells, 2010
Table 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015
Table 4.4 Some Companies in the Regenerative Medicine Sector, 2010
Table 4.5 Stem Cell Services: Sales Forecast ($m), 2010-2025
Table 4.6 Some Companies in the Stem Cell Services Market, 2010
Table 4.7 Cord Blood Banking: Sales Forecast ($m), 2010-2025
Table 4.8 Some Companies in the Cord Blood Banking Market, 2010
Table 5.1 Some Companies in the Embryonic Stem Cell Therapies Sector, 2010
Table 5.2 Some Companies in the Allogeneic Adult Stem Cell Therapies Sector, 2010
Table 5.3 Some Companies in the Autologous Adult Stem Cell Therapies Sector, 2010
Table 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025
Table 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025
Table 8.1 Total Stem Cells Market: Sales Forecast by Sector ($m), 2010-2025

List of Figures
Figure 4.1 Sectors of the Stem Cells Market: Sales ($bn), 2009
Figure 4.2 Bone Marrow Transplants: Sales Forecast ($m), 2010-2025
Figure 4.3 Osteocel Products: Sales Forecast ($m), 2010-2015
Figure 4.4 Stem Cell Services: Sales Forecast ($m), 2010-2025
Figure 4.5 Cord Blood Banking: Sales Forecast ($m), 2010-2025
Figure 6.1 Stem Cell Therapies: Sales Forecast ($m), 2010-2025
Figure 6.2 Total Stem Cells Market: Sales Forecast ($m), 2010-2025